Regeneron Pharmaceuticals Inc. (REGN)
Q2 2012 Earnings Call
July 25, 2012 8:30 am ET
Dr. Leonard Schleifer – President, Chief Executive Officer
Murray Goldberg – Chief Financial Officer
George Yancopoulos – Chief Science Officer, President – Regeneron Research Labs
Robert Terifay – Senior Vice President, Commercial
Dr. Michael Aberman – Vice President, Strategy and Investor Relations
Steve Byrne – Bank of America
Alethia Young – Deutsche Bank
Chris Raymond – Robert W. Baird
Terence Flynn – Goldman Sachs
Jim Birchenough – BMO Capital
Yaron Werber - Citigroup
Biren Amin – Jefferies
Mani Mohindru – ThinkEquity
Joseph Schwartz – Leerink Swann
Ted Tenthoff – Piper Jaffray
Phil Nadeau – Cowen & Company
Geoff Meacham – JP Morgan
Good morning ladies and gentlemen and welcome to the Regeneron Pharmaceuticals conference call to discuss the second quarter 2012 financial results. My name is Kevin and I’ll be your coordinator today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of this conference call. As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the call over to Dr. Michael Aberman, Vice President of Strategy and Investor Relations for Regeneron. Please proceed, Dr. Aberman.
Dr. Michael Aberman
Thank you, Operator, and good morning and welcome to Regeneron Pharmaceuticals’ second quarter 2012 conference call. An archive of this webcast will be available under Events and Presentations for 30 days. Joining me on the call today is Dr. Leonard Schleifer, the Founder, President and Chief Executive Officer; George Yancopoulos, Executive Vice President, Chief Scientific Officer and President of Regeneron Research Labs; Murray Goldberg, Chief Financial Officer, and Robert Terifay, Senior Vice President, Commercial. After our prepared remarks, we’ll open the call for Q&A.